The entire Ethismos team is dedicated to advancing and developing safe and effective therapies for addiction, depression and chronic pain that will have a positive impact on the lives of patients, their families and loved ones, and their communities.
The Ethismos team have years of development experience with the serotonin-preferring triple reuptake inhibitor amitifadine and recent success with a related triple centanafadine, a norepinephrine-preferring triple for ADHD now in Phase 3 with Otsuka Pharmaceuticals.
Ethismos has brought together many of the same team of scientists, researchers and development experts who advanced centanafadine from pre-IND through the end of Phase 2 stage prior to the sale to Otsuka (Ethismos predecessor company Neurovance is now wholly owned subsidiary of Otsuka) .
Anthony McKinney – Founder & CEO
An industry veteran with over 30 years of biotechnology and pharma experience, Tony has held senior positions in several successful emerging and established biotechnology companies including Novazyme (acquired by Genzyme) and Genzyme, a leading global biotechnology giant. Tony was founding executive at Orexigen Therapeutics, a biotechnology company (acquired by Nalpropion Pharmaceuticals), and founding CEO of Euthymics and Neurovance, predecessor companies to Ethismos.
Tony has played lead roles in the acquisition and consolidation of high-potential early stage biotechnology companies and has a track record of adding considerable shareholder value to emerging biotech companies through strategic partnerships and successful exits.
During his 30-year career Tony has led science, sales and operations teams, directed product development efforts, and managed corporate development and M&A functions. A highly regarded expert in the biotech innovation with 12 issued US patents and 48 pending US applications, multiple publications, major involvement in two US drug approvals, and over $300 million in private and public financing raised, Tony provides a unique skill set, insight and perspective on bringing therapies from “bench to buyout.”
Advisors - Ethismos has assembled a committed group of world-class clinicians, scientists, development partners, and business advisors who are well versed in addiction, genetics, drug development, manufacturing, regulatory & compliance, payer strategies, IP licensing & transfer strategy and cross boarder partnerships. As a team they are a wealth of knowledge, a key competitive advantage as Ethismos accelerates growth and advances toward landmark events.
Jennifer DiGiacinto, PharmD, Clinical Pharmacology consultant, RRD; former clinical pharmacology, FDA
Professor David Heal, CNS Pharmacology/abuse liability consultant, advisor to regulatory agencies, RenaSci, Ltd.
Jack Henningfield, PhD, VP, Research, Health Policy, and Abuse Liability, Pinney Associates; former NIDA
Maryann Krane, Senior VP of Program Leadership, Regulatory/CMC, RRD; former Genetics Institute, Ariad
Bridget Martell, MD, consulting CMO, RRD; Board certified in internal/addiction medicine
John McKinney, MA (Psychology), Clinical Operations; former Neurovance Manager, Clinical Operations
Robert van Lier, PhD, consulting toxicologist, former senior researcher Eli Lilly, Strategic Toxicology Consulting
Jürgen Venitz, MD, PhD, Professor, Virginia Commonwealth, ADME/PK consultant to FDA & pharma
A. Eden Evins, MD, Director of Addiction Medicine, Massachusetts General Hospital
Maurizio Fava, MD, Executive Chairman, Department of Psychiatry, Massachusetts General Hospital
Robert Jamison, PhD, Professor, Departments of Anesthesia and Psychiatry, Brigham & Women’s Hospital, Harvard Medical School
Jianren Mao, MD, PhD, Chief, Division of Pain Medicine, Massachusetts General Hospital
Edward Sellers, MD, PhD, Professor Emeritus, Pharmacology and Toxicology, Medicine, and Psychiatry, University of Toronto
Jed Rose, PhD, Director, Center for Smoking Cessation and Professor, Department of Psychiatry and Behavioral Sciences, Duke University
Joanna Starrels, MD, MS, Montefiore Medical Center, Albert Einstein College of Medicine, Nationally recognized opioid/chronic pain expert
Mark Sullivan, MD, PhD, Professor, Psychiatry and Behavioral Sciences Adjunct Professor, Anesthesiology and Pain Medicine, Bioethics and Humanities, University of Washington
Rachel Tyndale, PhD, Professor, Pharmacology & Toxicology; Psychiatry Endowed Chair in Addictions, Head Pharmacogenetics Centre for Addiction and Mental Health, University of Toronto
3rd Party Partners:
Alcami (API manufacturing)
Almac (clinical trial packaging)
Boston Analytical (analytical testing)
Cyprotex (GLP ADME testing)
Eurofins (formerly called EAG Labs) (analytical/stability)
Pharmaceutics International, Inc. (PII) (drug product manufacturing)
Premier (global CRO)
RRD International (regulatory/safety/clin-pharm/CMC/program management/medical writing)
Rose Research Center (clinical trials)